New drug cocktail aims to shrink melanoma before surgery
NCT ID NCT07336979
First seen Jan 19, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This phase 2 trial is testing whether giving a combination of chemotherapy (paclitaxel polymersomes and carboplatin) plus an immunotherapy drug (adebelimab) before surgery can help shrink tumors in people with resectable mucosal melanoma. About 32 participants will receive up to 3 cycles of treatment, then undergo surgery to remove any remaining cancer. The main goal is to see how many patients have a significant reduction in tumor cells after the drug combo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE MUCOSAL MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paclitaxel polymersomes, carboplatin, and adebelimab
What this could lead to
If successful, this approach could shrink tumors before surgery, potentially improving survival and reducing recurrence for people with resectable mucosal melanoma.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The drug combination may cause side effects like nerve damage, low blood counts, or immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.